高级检索
当前位置: 首页 > 详情页

18β-Glycyrrhetinic Acid Inhibits TGF-β-Induced Epithelial-to-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Targeting STAT3

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Hubei Key Lab Hepaio Pancreatobiliaty Dis, Clin Med Res Ctr Hepat Surg Hubei Prov,Minist Edu, Tongji Hosp,Tongji Med Coll,Hepat Surg Ctr,Key La, Wuhan, Hubei, Peoples R China [2]Minist Publ Hlth, Wuhan, Hubei, Peoples R China [3]Shanghai Jiao Tong Univ, Dept Gen Surg, Peoples Hosp 1, Shanghai, Peoples R China
出处:
ISSN:

关键词: 18 beta-Glycyrrhetinic Acid TGF-beta Epithelial-to-Mesenchymal Transition STAT3 Metastasis HCC Hepatocellular Carcinoma

摘要:
18 beta-glycyrrhetinic acid (GA) is the active ingredient of the traditional Chinese medicinal herb Glycyrrhizae radix et rhizoma. We previously demonstrated that GA inhibited tumor growth in hepatocellular carcinoma (HCC). However, the effect of GA on transforming growth factor-beta (TGF-beta)-induced epithelial-mesenchymal transition (EMT) and metastasis were still unclear. In this study, in vitro transwell assays and immunofluorescence (IF) demonstrated that GA inhibited TGF-beta-induced migration, invasion and EMT of HCC cells. However, it had little effect on the inhibition of proliferation by TGF-beta. Moreover, we confirmed that GA suppressed the metastasis of HCC cells in vivousing an ectopic lung metastasis model. Furthermore, we found that GA inhibited TGF-beta-induced EMT mainly by reducing the phosphorylation of signal transducer and activator of transcription 3 (STAT3), which played an essential role in TGF-beta-induced EMT and cell mobility. Mechanistically, GA inhibited the phosphorylation of STAT3 by increasing the expression of Src homology 2 domain-containing protein tyrosine phosphatases 1 and 2 (SHP1 and SHP2). Therefore, we concluded that GA inhibited TGF-beta-induced EMT and metastasis via the SHP1&SHP2/STAT3/Snail pathway. Our data provide an attractive therapeutic target for future multimodal management of HCC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 2 区 全科医学与补充医学 2 区 医学:内科
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 全科医学与补充医学 2 区 医学:内科
JCR分区:
出版当年[2020]版:
Q1 MEDICINE, GENERAL & INTERNAL Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE
最新[2023]版:
Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Hubei Key Lab Hepaio Pancreatobiliaty Dis, Clin Med Res Ctr Hepat Surg Hubei Prov,Minist Edu, Tongji Hosp,Tongji Med Coll,Hepat Surg Ctr,Key La, Wuhan, Hubei, Peoples R China [2]Minist Publ Hlth, Wuhan, Hubei, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Hubei Key Lab Hepaio Pancreatobiliaty Dis, Clin Med Res Ctr Hepat Surg Hubei Prov,Minist Edu, Tongji Hosp,Tongji Med Coll,Hepat Surg Ctr,Key La, Wuhan, Hubei, Peoples R China [2]Minist Publ Hlth, Wuhan, Hubei, Peoples R China [*1]Huazhong Univ Sci & Technol, Hepat Surg Ctr, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:0 总访问量:408 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)